Vinpocetine - instructions for use, dose, side effects, contraindications

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; enhances the transport of glucose to the brain, through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca ²⁺ - dependent phosphodiesterase; increases the levels of adenosine monophosphate, cyclic guanosine monophosphate and adenosine triphosphate of the brain. Strengthens the exchange of norepinephrine. and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the return of oxygen in the erythrocytes. Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation. Does not have the effect of "stealing" and enhances blood supply, especially in ischemic areas of the brain. Penetrates through the placental barrier.

Pharmacokinetics:

Quickly absorbed. Time to reach the maximum concentration in blood plasma - 1 hour. Absorption occurs mainly in the proximal parts of the gastrointestinal tract. When passing through the wall of the intestine is not exposed to metabolism. The maximum concentration in tissues is noted 2-4 hours after ingestion.Linkage with proteins - 66%, bioavailability with ingestion - 7%. Clearance 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates an extrahepatic metabolism. With repeated administration, the kinetics is linear. The half-life in humans is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the intestine in a ratio of 3: 2.

Indications:

reduction in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency (including the recovery stage of ischemic or hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, atherosclerosis of the vessels of the head brain; posttraumatic and hypertensive encephalopathy);
chronic vascular diseases of the choroid and retina;
hearing loss perceptive type, Meniere's disease, idiopathic tinnitus.

Contraindications:

acute phase of hemorrhagic stroke, severe ischemic heart disease, severe arrhythmias, hypersensitivity to any of the components of the drug.
pregnancy (possibly placental bleeding and spontaneous abortion, probably as a result of increased placental blood supply).
lactation period (with the drug should stop breastfeeding).
children under 18 years (due to insufficient data).

Dosing and Administration:

Inside, after eating, 3 times a day. The initial daily dose is 15 mg. The maximum daily dose is 30 mg. Duration of treatment to 3 months. In diseases of the kidneys or liver, the drug is prescribed in the usual dose.

Side effects:

From the side of the cardiovascular system: change in ECG (depression ST, lengthening the interval QT), tachycardia, extrasystole, lability of blood pressure, sensation of hot flashes.

From the central nervous system: sleep disturbances (insomnia or increased drowsiness), dizziness, headache.

On the part of the digestive system: dry mouth, nausea, heartburn.

Other: allergic reactions, general weakness, increased sweating.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Interactions are not observed when used simultaneously with P-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide, imipramine

The simultaneous use of vinpocetine and a-methyldopa sometimes caused some strengthening of the hypotensive effect, so this treatment requires regular monitoring of blood pressure.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic and anticoagulant action.

Special instructions:The presence of the syndrome of prolonged QT interval and the use of drugs that cause prolongation of the QT interval requires periodic ECG monitoring. In case of lactose intolerance, it should be taken into account that lactose is included in the formulation. Data on the effect of vinpocetine on the ability to drive a car and perform work that requires speed of psychomotor reactions is not.

Form release / dosage:Tablets 5 mg.

Packaging:10 tablets per contour cell pack. 2 or 5 contour mesh packages together with instructions for use in a pack of cardboard.

Storage conditions:

In a dry place protected from light. Keep away from children

Shelf life:

5 years. Do not use after the expiration date stated on the package

Terms of leave from pharmacies:On prescription

Registration number:LSR-005753/08

Date of registration:22.07.2008

The owner of the registration certificate:IRBITSK HFZ, OJSC IRBITSK HFZ, OJSC Russia

Manufacturer: & nbsp

IRBITSK HFZ, OJSC Russia

Information update date: & nbsp11.10.15

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)